clenbuterol has been researched along with Atrophy in 9 studies
Clenbuterol: A substituted phenylaminoethanol that has beta-2 adrenomimetic properties at very low doses. It is used as a bronchodilator in asthma.
clenbuterol : A substituted aniline that is 2,6-dichloroaniline in which the hydrogen at position 4 has been replaced by a 2-(tert-butylamino)-1-hydroxyethyl group.
Atrophy: Decrease in the size of a cell, tissue, organ, or multiple organs, associated with a variety of pathological conditions such as abnormal cellular changes, ischemia, malnutrition, or hormonal changes.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Clenbuterol (Clen), a beta(2)-agonist, is known to produce skeletal and myocardial hypertrophy." | 3.73 | Effects of chronic administration of clenbuterol on function and metabolism of adult rat cardiac muscle. ( Karbowska, J; Kochan, Z; Latif, N; Malik, A; Smolenski, RT; Soppa, GK; Terracciano, CM; Yacoub, MH; Yuen, AH, 2005) |
| "During complete LV unloading, clenbuterol did not prevent myocardial atrophy but improved gene expression (SERCA2a, beta-MHC) and beta-adrenergic responsiveness and potentially prevented myocardial apoptosis." | 3.73 | Does the beta2-agonist clenbuterol help to maintain myocardial potential to recover during mechanical unloading? ( Ikeda, T; Kanemitsu, H; Komeda, M; Matsuoka, S; Nishina, T; Oriyanhan, W; Shiina, R; Tsuneyoshi, H, 2005) |
| " We studied changes in MLC2 phosphorylation in rats receiving three treatment conditions causing slow-to-fast transitions: 1) atrophy induced by 14 days of hindlimb suspension (HS), 2) hypertrophy induced by 14 days of clenbuterol administration (CB), and 3) 14 days of combined treatment (CB-HS)." | 3.72 | Increased phosphorylation of myosin light chain associated with slow-to-fast transition in rat soleus. ( Bozzo, C; Mounier, Y; Reggiani, C; Stevens, L; Toniolo, L, 2003) |
| "Heart failure is a widespread condition in the United States that is predicted to significantly increase in prevalence in the next decade." | 2.61 | Left ventricular assist device recovery: does duration of mechanical support matter? ( Chaparro, SV; Pham, BN, 2019) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (11.11) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 6 (66.67) | 29.6817 |
| 2010's | 2 (22.22) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Pham, BN | 1 |
| Chaparro, SV | 1 |
| Pokorný, M | 1 |
| Cervenka, L | 1 |
| Netuka, I | 1 |
| Pirk, J | 1 |
| Koňařík, M | 1 |
| Malý, J | 1 |
| Bozzo, C | 1 |
| Stevens, L | 3 |
| Toniolo, L | 1 |
| Mounier, Y | 2 |
| Reggiani, C | 2 |
| Pellegrino, MA | 1 |
| D'Antona, G | 1 |
| Bortolotto, S | 1 |
| Boschi, F | 1 |
| Pastoris, O | 1 |
| Bottinelli, R | 1 |
| Polla, B | 1 |
| Soppa, GK | 1 |
| Smolenski, RT | 1 |
| Latif, N | 1 |
| Yuen, AH | 1 |
| Malik, A | 1 |
| Karbowska, J | 1 |
| Kochan, Z | 1 |
| Terracciano, CM | 1 |
| Yacoub, MH | 1 |
| Tsuneyoshi, H | 1 |
| Oriyanhan, W | 1 |
| Kanemitsu, H | 1 |
| Shiina, R | 1 |
| Nishina, T | 1 |
| Matsuoka, S | 1 |
| Ikeda, T | 1 |
| Komeda, M | 1 |
| Firinga, C | 1 |
| Gohlsch, B | 1 |
| Bastide, B | 1 |
| Pette, D | 1 |
| Canu, M | 1 |
| Ricart-Firinga, C | 1 |
| Picquet, F | 1 |
| Falempin, M | 1 |
| Zeman, RJ | 1 |
| Ludemann, R | 1 |
| Etlinger, JD | 1 |
2 reviews available for clenbuterol and Atrophy
| Article | Year |
|---|---|
Left ventricular assist device recovery: does duration of mechanical support matter?
Topics: Adult; Atrophy; Calcium; Cardiomyopathy, Dilated; Clenbuterol; Female; Heart; Heart Failure; Heart T | 2019 |
Ventricular assist devices in heart failure: how to support the heart but prevent atrophy?
Topics: Adrenergic beta-Agonists; Animals; Atrophy; Clenbuterol; Heart Failure; Heart-Assist Devices; Humans | 2014 |
7 other studies available for clenbuterol and Atrophy
| Article | Year |
|---|---|
Increased phosphorylation of myosin light chain associated with slow-to-fast transition in rat soleus.
Topics: Adrenergic beta-Agonists; Animals; Atrophy; Cardiac Myosins; Clenbuterol; Hindlimb Suspension; Hyper | 2003 |
Clenbuterol antagonizes glucocorticoid-induced atrophy and fibre type transformation in mice.
Topics: Adrenergic beta-Agonists; Animals; Atrophy; Clenbuterol; Dexamethasone; Diaphragm; Drug Interactions | 2004 |
Effects of chronic administration of clenbuterol on function and metabolism of adult rat cardiac muscle.
Topics: Adrenergic beta-Agonists; Age Factors; Animals; Atrophy; Calcium; Carbohydrate Metabolism; Citric Ac | 2005 |
Does the beta2-agonist clenbuterol help to maintain myocardial potential to recover during mechanical unloading?
Topics: Adrenergic beta-Agonists; Animals; Atrophy; Calcium-Transporting ATPases; Caspase 3; Caspases; Clenb | 2005 |
Effects of unweighting and clenbuterol on myosin light and heavy chains in fast and slow muscles of rat.
Topics: Adrenergic beta-Agonists; Animals; Atrophy; Body Weight; Clenbuterol; Hindlimb; Hindlimb Suspension; | 2000 |
Effect of the beta(2)-agonist clenbuterol on the locomotor activity of rat submitted to a 14-day period of hypodynamia-hypokinesia.
Topics: Adrenergic beta-Agonists; Animals; Atrophy; Clenbuterol; Electromyography; Hindlimb Suspension; Male | 2001 |
Clenbuterol, a beta 2-agonist, retards atrophy in denervated muscles.
Topics: Animals; Atrophy; Clenbuterol; Ethanolamines; Female; Isometric Contraction; Muscle Denervation; Mus | 1987 |